{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "21031626", "DateCompleted": {"Year": "2011", "Month": "01", "Day": "18"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "11"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1002/ptr.3189"], "Journal": {"ISSN": "1099-1573", "JournalIssue": {"Volume": "24", "Issue": "11", "PubDate": {"Year": "2010", "Month": "Nov"}}, "Title": "Phytotherapy research : PTR", "ISOAbbreviation": "Phytother Res"}, "ArticleTitle": "Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside.", "Pagination": {"StartPage": "1670", "EndPage": "1675", "MedlinePgn": "1670-5"}, "Abstract": {"AbstractText": ["Tiliroside, an active flavonoid extensively found in many medicinal plants including Helichrysum italicum, Geranium mexicanum and Helianthemum glomeratum, has been demonstrated to exert multiple biological effects including antiinflammatory, antimicrobial, antioxidant and antitumor activities. Cytochrome P450 (CYP) enzymes play an important role in the Phase I oxidation metabolism of a wide range of xenobiotics and inhibition of CYP isoforms might influence the elimination of drugs and induce serious adverse drug response. The inhibition of seven CYP isoforms (CYP3A4, CYP1A2, CYP2A6, CYP2D6, CYP2C9, CYP2C8 and CYP2E1) by tiliroside was investigated using in vitro human liver microsomal incubation assays. The results showed that tiliroside strongly inhibited the activity of CYP3A4 (IC(50) = 9.0 \u00b1 1.7 \u03bcm), CYP2C8 (IC(50) = 12.1 \u00b1 0.9 \u03bcm) and CYP2C9 (IC(50) = 10.2 \u00b1 0.9 \u03bcm) with other CYP isoforms negligibly influenced. Further kinetic analysis showed that inhibition of these three CYP isoforms by tiliroside is best fit to a competitive way. The K(i) value was calculated to be 5.5 \u03bcm, 3.3 \u03bcm, 9.4 \u03bcm for CYP3A4, CYP2C9 and CYP2C8, respectively. The relatively low K(i) values suggested that tiliroside might induce drug-drug interactions with many clinically used drugs which are mainly metabolized by these three CYP isoforms. Therefore, attention should be given to the probable drug-drug interaction between tiliroside-containing herbs and substrates of CYP3A4, CYP2C9 and CYP2C8."], "CopyrightInformation": "Copyright \u00a9 2010 John Wiley & Sons, Ltd."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Traditional Chinese Medicine, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang, 110016, China."}], "Identifier": [], "LastName": "Sun", "ForeName": "Dong-Xue", "Initials": "DX"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lu", "ForeName": "Jin-Cai", "Initials": "JC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Fang", "ForeName": "Zhong-Ze", "Initials": "ZZ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Yan-Yan", "Initials": "YY"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Cao", "ForeName": "Yun-Feng", "Initials": "YF"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Mao", "ForeName": "Yu-Xi", "Initials": "YX"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhu", "ForeName": "Liang-Liang", "Initials": "LL"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yin", "ForeName": "Jun", "Initials": "J"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yang", "ForeName": "Ling", "Initials": "L"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Phytother Res", "NlmUniqueID": "8904486", "ISSNLinking": "0951-418X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cytochrome P-450 CYP3A Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavonoids"}, {"RegistryNumber": "15M04TXR9M", "NameOfSubstance": "tiliroside"}, {"RegistryNumber": "EC 1.14.13.-", "NameOfSubstance": "CYP2C9 protein, human"}, {"RegistryNumber": "EC 1.14.13.-", "NameOfSubstance": "Cytochrome P-450 CYP2C9"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Aryl Hydrocarbon Hydroxylases"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "CYP2C8 protein, human"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP2C8"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP3A"}, {"RegistryNumber": "EC 1.14.14.55", "NameOfSubstance": "CYP3A4 protein, human"}], "MeshHeadingList": [{"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Aryl Hydrocarbon Hydroxylases"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP2C8"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP2C9"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP3A"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP3A Inhibitors"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Flavonoids"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["drug effects"], "DescriptorName": "Microsomes, Liver"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2010", "Month": "10", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "10", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2011", "Month": "1", "Day": "19", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["21031626", "10.1002/ptr.3189"]}}], "PubmedBookArticle": []}